Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Scheel AK et al. | Severe neurotoxicity of tacrolimus (FK506) after renal transplantation: two case reports. | 2001 Nov-Dec | Transplant. Proc. | pmid:11750573 |
Morris-Stiff G et al. | Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. | 1998 | Transplant. Proc. | pmid:9636525 |
Jordan ML et al. | FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. | 1993 | Transplant. Proc. | pmid:7679827 |
Montejo M et al. | Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+/R-) liver transplant recipients: a single-center experience. | 2009 Jul-Aug | Transplant. Proc. | pmid:19715869 |
Jusko WJ and D'Ambrosio R | Monitoring FK 506 concentrations in plasma and whole blood. | 1991 | Transplant. Proc. | pmid:1721260 |
Sher LS et al. | Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. | 1996 | Transplant. Proc. | pmid:8623212 |
Barrera-Pulido L et al. | Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications. | 2009 Jul-Aug | Transplant. Proc. | pmid:19715870 |
Millis JM et al. | Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. | 1996 | Transplant. Proc. | pmid:8623213 |
Peddi VR et al. | Tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. | 1998 | Transplant. Proc. | pmid:9532151 |
Burke GW et al. | Cholesterol control: long-term benefit of pancreas-kidney transplantation with FK 506 immunosuppression. | 1998 | Transplant. Proc. | pmid:9532153 |
Staschak S et al. | A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. | 1990 | Transplant. Proc. | pmid:1689896 |
Pérez MJ et al. | Cardiovascular risk factors after liver transplantation: analysis of related factors. | 2011 | Transplant. Proc. | pmid:21486587 |
Manu M et al. | Impact of tacrolimus on hyperlipidemia after renal transplantation: a Japanese single center experience. | 2000 | Transplant. Proc. | pmid:11119912 |
Tsang WK et al. | Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients. | 2000 | Transplant. Proc. | pmid:11119921 |
Žilinská Z et al. | Impact of Trough Levels of Tacrolimus on Kidney Function and Graft Survival in Short and Longer Periods After Renal Transplantation. | 2016 | Transplant. Proc. | pmid:27788794 |
Faivre L et al. | FK 506 dose in transplantation: from theory to practice. | 2001 | Transplant. Proc. | pmid:11406256 |
Chan KL et al. | Porcine small bowel transplantation with FK506 as a single immunosuppressant. | 2001 | Transplant. Proc. | pmid:11406260 |
Kaplinsky E et al. | Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients. | 2012 | Transplant. Proc. | pmid:23146455 |
Platz KP et al. | Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. | 1998 | Transplant. Proc. | pmid:9636596 |
McLachlan G et al. | Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721291 |
Akselband Y et al. | Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. | 1991 | Transplant. Proc. | pmid:1721292 |
D'Silva M et al. | Immunosuppressive effect of brequinar on rat cardiac allograft survival in combination with leflunomide or FK 506. | 1996 | Transplant. Proc. | pmid:8623476 |
Klintmalm GB | Clinical use of FK 506 in liver transplantation. | 1996 | Transplant. Proc. | pmid:8623484 |
Egawa H et al. | Lymphoproliferative disorders in patients undergoing living-related liver transplantation. | 1998 | Transplant. Proc. | pmid:9474982 |
Alloway R et al. | Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. | 2005 | Transplant. Proc. | pmid:15848559 |
Tellis V et al. | No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation. | 2005 | Transplant. Proc. | pmid:15848571 |
Sawai T et al. | A successful induction of tolerance by perioperative intrathymic injection in rat "high-responder" heart transplantation. | 1999 | Transplant. Proc. | pmid:10578275 |
Uchida H et al. | Chronopharmacology of tacrolimus in rats: toxicity and efficacy in a mouse-to-rat intestinal transplant model and its pharmacokinetic profile. | 1999 | Transplant. Proc. | pmid:10578276 |
Akbas SH et al. | Evaluation of the new EMIT tacrolimus assay in kidney and liver transplant recipients. | 2004 Jan-Feb | Transplant. Proc. | pmid:15013308 |
Yasunami Y et al. | Induction of donor-specific unresponsiveness in rat islet allografts by FK 506. | 1992 | Transplant. Proc. | pmid:1376510 |
Martinez OM et al. | Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. | 1995 | Transplant. Proc. | pmid:7533372 |
Motta I et al. | FK 506 favors the generation of memory T cells in vitro. | 1991 | Transplant. Proc. | pmid:1721324 |
Isai H et al. | FK 506 and orthotopic liver transplantation in the rat. | 1990 | Transplant. Proc. | pmid:1699329 |
Li J et al. | Regulatory effect of FK506 on CD152 and PD-1 in the liver allorecipients. | 2008 | Transplant. Proc. | pmid:18589137 |
Choi SJ et al. | Tacrolimus-induced apoptotic signal transduction pathway. | 2008 | Transplant. Proc. | pmid:18929848 |
Bäckman L et al. | Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity. | 1994 | Transplant. Proc. | pmid:7518160 |
Hoshinaga K et al. | Regimen of tacrolimus-based immunosuppression with basiliximab, mycophenolate mofetil, and low-dose steroid reduces acute rejection in kidney transplants. | 2005 | Transplant. Proc. | pmid:15919457 |
Junge G et al. | Microchimerism in patients after orthotopic liver transplantation: a prognostic indicator? | 2002 | Transplant. Proc. | pmid:12176475 |
Sarvary E et al. | De novo Prograf versus de novo Advagraf: are trough level profile curves similar? | Transplant. Proc. | pmid:25131131 | |
Kilian K et al. | FK-506 (tacrolimus) therapy for an unusual SLE-like disease. | 1998 | Transplant. Proc. | pmid:9865322 |
Laskow DA et al. | Phase II FK 506 multicenter concentration control study: one-year follow-up. | 1995 | Transplant. Proc. | pmid:7533431 |
Shapiro R et al. | A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. | 1995 | Transplant. Proc. | pmid:7533432 |
Reyes J et al. | Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721355 |
Whiteside TL et al. | Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721356 |
Barrera-Pulido L et al. | Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. | 2008 | Transplant. Proc. | pmid:19010156 |
Marqués E et al. | Development of lymphoproliferative disease after liver transplantation. | 2008 | Transplant. Proc. | pmid:19010169 |
Perego C et al. | Orthotopic liver-small bowel transplantation in pigs: study of immunologic parameters during therapy with FK 506-based immunosuppressive regimens. | 1996 | Transplant. Proc. | pmid:8907908 |
Hayakawa K et al. | Involvement of clonal deletion in immunotolerance induction: tests of Tacrolimus administration in rat renal transplantation. | 1994 | Transplant. Proc. | pmid:7520608 |
Pascual J et al. | A low incidence of new-onset insulin-dependent diabetes mellitus using tacrolimus in kidney recipients in Europe. | 2003 | Transplant. Proc. | pmid:12962785 |
Moreno JM et al. | Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. | 2003 | Transplant. Proc. | pmid:12962831 |
Guy S et al. | Successful treatment of acute severe graft-versus-host-disease in a pancreas-after-kidney transplant recipient: case report. | 2014 | Transplant. Proc. | pmid:25179161 |
Rashid I et al. | Medium-term outcome using sirolimus-tacrolimus combination in adult renal transplant recipients. | 2002 | Transplant. Proc. | pmid:12176520 |
Shapiro R et al. | A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. | 2002 | Transplant. Proc. | pmid:12176521 |
Fukushima N et al. | Prolonged survival of pig cardiac xenografts in baboons by sequential cardiac transplantation. | 1998 | Transplant. Proc. | pmid:9838671 |
Schulz T et al. | Mycophenolate mofetil/prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083251 |
Nishimura Y et al. | A trial to obtain donor-specific immunotolerance using a vascularized thymus allograft. | 1998 | Transplant. Proc. | pmid:9838684 |
Damotte D et al. | Morphologic features of large bowel biopsies in combined small and large bowel transplantations could predict clinical rejection. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083252 |
Thomson AW et al. | Immunosuppressive activity, T-cell subset analysis, and acute toxicity of FK-506 in rats. | 1989 | Transplant. Proc. | pmid:2468203 |
Hossein-Nia M et al. | Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721388 |
Sanghvi A et al. | Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. | 1989 | Transplant. Proc. | pmid:2468204 |
Winkler M et al. | Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. | 1991 | Transplant. Proc. | pmid:1721389 |
Akutsu N et al. | Two cases of calcineurin inhibitor-associated reversible posterior leukoencephalopathy syndrome in renal transplant recipients. | 2008 | Transplant. Proc. | pmid:18790253 |
Burke GW et al. | Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: evidence for augmentation of chimerism. | 1997 Feb-Mar | Transplant. Proc. | pmid:9123275 |
Ota H et al. | Intrathymic microchimerism predicts rejection response in allograft recipients. | 1997 Feb-Mar | Transplant. Proc. | pmid:9123279 |
Kiuchi T et al. | Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. | 1996 | Transplant. Proc. | pmid:8962229 |
Personett HA et al. | Impact of molecular adsorbent recirculating system therapy on tacrolimus elimination: a case report. | 2014 | Transplant. Proc. | pmid:25017243 |
Arita S et al. | Effect of FK 506 in experimental pancreas transplantation. | 1995 | Transplant. Proc. | pmid:7536980 |
Bunnapradist S and Takemoto SK | Controlling treatment allocation bias in a registry analysis when comparing calcineurin inhibitors. | 2003 | Transplant. Proc. | pmid:14611971 |
Suwelack B et al. | Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels. | 2002 | Transplant. Proc. | pmid:12176585 |
Salizzoni M et al. | Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation. | 2001 | Transplant. Proc. | pmid:11377521 |
El Haggan W et al. | One year evolution of bone mineral density in kidney transplant recipients receiving tacrolimus versus cyclosporine. | 2002 | Transplant. Proc. | pmid:12176589 |
Orsenigo R et al. | FK506 and SMS 201-995: effect on heterotopic heart transplantation in rats. | 2001 Feb-Mar | Transplant. Proc. | pmid:11266956 |
Ishibashi M et al. | Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding C(max). | 2001 Feb-Mar | Transplant. Proc. | pmid:11266958 |
Mendes J et al. | Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. | 2009 | Transplant. Proc. | pmid:19376366 |
McMaster P et al. | Liver transplantation: changing goals in immunosuppression. | 1998 | Transplant. Proc. | pmid:9723295 |
Gibelli NE et al. | Sirolimus in pediatric liver transplantation: a single-center experience. | 2009 | Transplant. Proc. | pmid:19376384 |
Cooper MH et al. | The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. | 1991 | Transplant. Proc. | pmid:1721419 |
Yagura K et al. | Pharmacokinetic characteristics of two types of liposomal FK 506. | 1996 | Transplant. Proc. | pmid:8658708 |
Van Buren D et al. | Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients. | 1998 | Transplant. Proc. | pmid:9723299 |
Ash MM and Jolly PS | A Case Report of the Resolution of Multiple Recalcitrant Verrucae in a Renal Transplant Recipient After a Mycophenolate Mofetil Dose Reduction. | Transplant. Proc. | pmid:28104140 | |
Navaneethan SD et al. | Tacrolimus-associated hypomagnesemia in renal transplant recipients. | 2006 | Transplant. Proc. | pmid:16797291 |
Moreno M et al. | Clinical management of tacrolimus drug interactions in renal transplant patients. | 1999 | Transplant. Proc. | pmid:10500564 |
Tur MD et al. | Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. | 2000 | Transplant. Proc. | pmid:11134804 |
Nikolaidis NL et al. | Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. | 1991 | Transplant. Proc. | pmid:1721450 |
Abu-Elmagd K et al. | Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. | 1991 | Transplant. Proc. | pmid:1721451 |
Reiner J et al. | After Intestinal Transplantation Kidney Function Is Impaired by Downregulation of Epithelial Ion Transporters in the Ileum. | 2016 | Transplant. Proc. | pmid:27109987 |
Ochiai T et al. | Studies on FK506 in experimental organ transplantation. | 1988 | Transplant. Proc. | pmid:2450414 |
Rao B et al. | Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. | 2016 | Transplant. Proc. | pmid:27109983 |
Immunosuppression: FK506. | 1988 | Transplant. Proc. | pmid:2450415 | |
Fung JJ et al. | Current status of FK 506 in liver transplantation. | 1991 | Transplant. Proc. | pmid:1712133 |
Bahra M et al. | Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage. | 2002 | Transplant. Proc. | pmid:12431663 |
Hesse CJ et al. | Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients. | 2002 | Transplant. Proc. | pmid:12431679 |
Miura S et al. | Effect of tacrolimus on the outcome of renal transplantation with donor-specific blood transfusion. | 1998 | Transplant. Proc. | pmid:9636492 |
Preston R et al. | FK 506 as primary immunosuppressive therapy in renal transplantation. | 1998 | Transplant. Proc. | pmid:9636493 |
Wu J et al. | Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. | 1991 | Transplant. Proc. | pmid:1703683 |
van Hooff JP et al. | Preservation of renal function and cardiovascular risk factors. | 2006 | Transplant. Proc. | pmid:16979974 |
Guleria S et al. | Tacrolimus (Pan Graf) as de novo therapy in renal transplant recipients in India. | 2006 | Transplant. Proc. | pmid:16979989 |
Socci C et al. | Pancreata from pediatric donors restore insulin independence in adult insulin-dependent diabetes mellitus recipients. | 2010 Jul-Aug | Transplant. Proc. | pmid:20692410 |
White SA et al. | Effect of acute rejection on expression of fibrosis associated genes in renal transplant recipients. | 2000 | Transplant. Proc. | pmid:10700949 |
Martins L et al. | Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity? | 2004 | Transplant. Proc. | pmid:15194300 |